In this episode, we examine funding uncertainty for genomic profiling through OMICO, structural tensions within the PBS and pharmaceutical supply chain, and broader concerns about how political and financial incentives shape health policy and budget decisions. The episode concludes with an uncomfortable discussion of recent public commentary on hostility against some communities (trigger warning).

Australia’s system for deciding whether new health technologies are funded is too focused on contested models and not enough on real people and their needs. The lack of human consideration leads to long delays, avoidable suffering, and sometimes deaths, in a process where patient voices are 'summarised' into oblivion while insiders talk around the problem instead of fixing it quickly, openly, and based on our shared values.

Reflect on Susan Ley’s legacy as a former health minister, especially the 2015 PBS Access and Sustainability Package. She was treated rudely and unfairly, and that meaningful ecosystem reform has since stalled. Critique Senate Estimates, noting that departmental witnesses were evasive and overly defensive, with patients largely absent from the conversation. The discussion expands to reform and the lack of patient rights. Also note the troubling political rhetoric about medical information and regulation. Close by teasing upcoming upgrades to the BPD website.

Mark Butler’s four 'pillars' on medicines policy and the argument that Australia prioritises low prices over preventing shortages and ensuring access. Do we need smarter, targeted incentives to address shortages that often reflect global challenges? Is there a risk of 'process creep' that actually slows access? Aged-care reforms that unintentionally removed funding for dose administration aids and glucose monitoring.

The Government has announced an additional $25 billion for public hospitals over five years, representing close to two PBSs, while NDIS spending is still rising by $1 billion every few months. Can anyone seriously still argue that there is no new money available to invest in medicines?

Not for the first time, some Australian politicians are in trouble over their use of very generous travel entitlements. We discuss why it matters for patients and why the claim that they are acting within the rules does not stack up.

A turbulent round of Senate Estimates, highlighted by a heartbreaking exchange about a mother with two children battling Crohn’s disease. Officials suggested that the family seek compassionate access from companies or seek treatment at a public hospital. We also canvass ‘MFN’ pricing risks, FOI controversies, ministerial travel blowouts and looming budget pressures that do not operate according to what might be a common understanding.